glyburide has been researched along with Epilepsy in 15 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study also investigates the effects of a mild epileptic insult on neuronal death in rat hippocampus after a subsequent, lethal epileptic stress using kainic acid (KA) as a model of epilepsy." | 3.70 | Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels. ( Blondeau, N; Heurteaux, C; Lazdunski, M; Plamondon, H, 1999) |
| "Hypotonia was the symptom that responded best." | 2.82 | Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses. ( Beltrand, J; Berdugo, M; Bernardo, WM; de Gouveia Buff Passone, C; Garcin, L; Giani, E; Kariyawasam, D; Polak, M; Vaivre-Douret, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| de Gouveia Buff Passone, C | 1 |
| Giani, E | 1 |
| Vaivre-Douret, L | 1 |
| Kariyawasam, D | 1 |
| Berdugo, M | 1 |
| Garcin, L | 1 |
| Beltrand, J | 1 |
| Bernardo, WM | 1 |
| Polak, M | 1 |
| Prado-Carro, AM | 1 |
| Calzada-Hernández, J | 1 |
| Marín, S | 1 |
| Cardona-Hernandez, R | 1 |
| Oriola, J | 1 |
| Nicolás, M | 1 |
| Ramon-Krauel, M | 1 |
| Oka, H | 1 |
| Suzuki, S | 1 |
| Furuya, A | 1 |
| Matsuo, K | 1 |
| Amamiya, S | 1 |
| Oshima, M | 1 |
| Oka, T | 1 |
| Mukai, T | 1 |
| Okayama, A | 1 |
| Araki, A | 1 |
| Azuma, H | 1 |
| Tanahashi, Y | 1 |
| Hashimoto, Y | 1 |
| Dateki, S | 1 |
| Hirose, M | 1 |
| Satomura, K | 1 |
| Sawada, H | 1 |
| Mizuno, H | 1 |
| Sugihara, S | 1 |
| Maruyama, K | 1 |
| Urakami, T | 1 |
| Sugawara, H | 1 |
| Shirai, K | 1 |
| Yorifuji, T | 1 |
| Ioacara, S | 1 |
| Flanagan, S | 1 |
| Fröhlich-Reiterer, E | 1 |
| Goland, R | 1 |
| Fica, S | 1 |
| Della Manna, T | 1 |
| Battistim, C | 1 |
| Radonsky, V | 1 |
| Savoldelli, RD | 1 |
| Damiani, D | 1 |
| Kok, F | 1 |
| Pearson, ER | 1 |
| Ellard, S | 2 |
| Hattersley, AT | 4 |
| Reis, AF | 1 |
| Mohamadi, A | 1 |
| Clark, LM | 1 |
| Lipkin, PH | 1 |
| Mahone, EM | 1 |
| Wodka, EL | 1 |
| Plotnick, LP | 1 |
| Jones, AG | 1 |
| Battaglia, D | 1 |
| Lin, YW | 1 |
| Brogna, C | 1 |
| Crinò, A | 1 |
| Grasso, V | 1 |
| Mozzi, AF | 1 |
| Russo, L | 1 |
| Spera, S | 1 |
| Colombo, C | 1 |
| Ricci, S | 1 |
| Nichols, CG | 1 |
| Mercuri, E | 1 |
| Barbetti, F | 1 |
| Slingerland, AS | 1 |
| Nuboer, R | 1 |
| Hadders-Algra, M | 1 |
| Bruining, GJ | 1 |
| Shimomura, K | 1 |
| Hörster, F | 1 |
| de Wet, H | 1 |
| Flanagan, SE | 1 |
| Wolf, NI | 1 |
| Ashcroft, F | 1 |
| Ebinger, F | 1 |
| Thorin, E | 1 |
| Nguyen, TD | 1 |
| Bouthillier, A | 1 |
| Plamondon, H | 1 |
| Blondeau, N | 1 |
| Heurteaux, C | 1 |
| Lazdunski, M | 1 |
| Wang, H | 1 |
| Wang, ZA | 1 |
| He, RR | 1 |
| Hildick-Smith, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 Gene[NCT05751525] | 21 participants (Anticipated) | Observational | 2016-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glyburide and Epilepsy
| Article | Year |
|---|---|
Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.
Topics: Adult; Child; Diabetes Mellitus; Epilepsy; Glyburide; Humans; Infant, Newborn; Infant, Newborn, Dise | 2022 |
14 other studies available for glyburide and Epilepsy
| Article | Year |
|---|---|
Patient with iDEND syndrome-related mutation.
Topics: Diabetes Mellitus; Epilepsy; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Infant | 2014 |
Glycemic control and motor development in a patient with intermediate DEND.
Topics: Child Development; Diabetes Mellitus; Epilepsy; Glucose; Glyburide; Humans; Infant; Infant, Newborn, | 2014 |
Molecular and clinical features of K
Topics: Amino Acid Substitution; Congenital Hyperinsulinism; Diabetes Mellitus; DNA Mutational Analysis; Dru | 2017 |
First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
Topics: Developmental Disabilities; Diabetes Mellitus; Epilepsy; Glyburide; Humans; Hypoglycemic Agents; Inf | 2017 |
Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
Topics: Brazil; Child, Preschool; Developmental Disabilities; Diabetes Mellitus; Epilepsy; Female; Glyburide | 2008 |
Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
Topics: Administration, Oral; Adolescent; Continuity of Patient Care; Developmental Disabilities; Diabetes M | 2010 |
Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age.
Topics: Administration, Oral; Adolescent; Amino Acid Substitution; Developmental Disabilities; Diabetes Mell | 2010 |
Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation.
Topics: Child; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Epilepsy; Glyburide; Glycat | 2012 |
Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the
Topics: Amino Acid Substitution; Blood Glucose; Developmental Disabilities; Diabetes Mellitus; Epilepsy; Fol | 2006 |
A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
Topics: Animals; Anticonvulsants; Cell Membrane; Child, Preschool; Developmental Disabilities; Diabetes Mell | 2007 |
Control of vascular tone by endogenous endothelin-1 in human pial arteries.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Arteries; Brain Neoplasms; Cerebral Cortex; Endothelin | 1998 |
Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels.
Topics: Animals; Disease Models, Animal; DNA Fragmentation; Epilepsy; Glyburide; Hippocampus; In Situ Nick-E | 1999 |
[Adenosine inhibits spontaneous and glutamate induced discharges of hippocampal CA1 neurons].
Topics: Adenosine; Animals; Electrophysiology; Epilepsy; Female; Glutamic Acid; Glyburide; Hippocampus; In V | 2000 |
Epilepsy in the elderly.
Topics: Age Factors; Aged; Angiography; Brain Neoplasms; Cerebrovascular Disorders; Dementia; Electroencepha | 1974 |